Shattuck Labs, Inc. $STTK Shares Purchased by Algert Global LLC

Algert Global LLC increased its position in Shattuck Labs, Inc. (NASDAQ:STTK) by 47.2% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 421,187 shares of the company’s stock after buying an additional 135,115 shares during the period. Algert Global LLC’s holdings in Shattuck Labs were worth $2,923,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently modified their holdings of STTK. Virtu Financial LLC acquired a new position in shares of Shattuck Labs during the third quarter valued at $38,000. AQR Capital Management LLC lifted its holdings in shares of Shattuck Labs by 265.4% during the 1st quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock valued at $41,000 after purchasing an additional 31,355 shares in the last quarter. Qube Research & Technologies Ltd bought a new stake in shares of Shattuck Labs during the second quarter worth $44,000. Squarepoint Ops LLC bought a new stake in shares of Shattuck Labs in the third quarter valued at about $46,000. Finally, Bridgeway Capital Management LLC lifted its stake in Shattuck Labs by 147.5% in the 2nd quarter. Bridgeway Capital Management LLC now owns 92,300 shares of the company’s stock valued at $73,000 after acquiring an additional 55,000 shares in the last quarter. Institutional investors and hedge funds own 58.74% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on STTK shares. Leerink Partners started coverage on Shattuck Labs in a research note on Monday, July 20th. They set an “outperform” rating and a $16.00 target price for the company. Needham & Company LLC raised their price objective on Shattuck Labs from $14.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday, June 8th. TD Cowen upgraded shares of Shattuck Labs to a “strong-buy” rating in a research report on Monday, August 24th. Wedbush raised their price target on shares of Shattuck Labs from $8.00 to $11.00 and gave the company an “outperform” rating in a research note on Friday, May 8th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Shattuck Labs in a research report on Friday, July 24th. They set an “overweight” rating and a $10.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $12.78.

Shattuck Labs Price Performance

NASDAQ STTK opened at $7.04 on Friday. The stock has a market capitalization of $706.53 million, a PE ratio of -13.80 and a beta of 1.08. Shattuck Labs, Inc. has a 1-year low of $0.97 and a 1-year high of $8.33. The business has a 50 day simple moving average of $7.05 and a two-hundred day simple moving average of $6.21.

Shattuck Labs (NASDAQ:STTK) last posted its earnings results on Tuesday, August 11th. The company reported ($0.12) earnings per share for the quarter, meeting the consensus estimate of ($0.12). On average, analysts anticipate that Shattuck Labs, Inc. will post -0.44 EPS for the current fiscal year.

Insider Activity

In other news, insider Abhinav A. Shukla sold 23,365 shares of the business’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $7.08, for a total value of $165,424.20. Following the completion of the sale, the insider owned 86,380 shares of the company’s stock, valued at approximately $611,570.40. The trade was a 21.29% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Arundathy N. Pandite sold 30,000 shares of the company’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $7.01, for a total transaction of $210,300.00. Following the completion of the sale, the insider directly owned 136,219 shares of the company’s stock, valued at $954,895.19. The trade was a 18.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 53,875 shares of company stock worth $379,305. 8.79% of the stock is currently owned by corporate insiders.

Shattuck Labs Company Profile

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical?stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten?carrier conjugate technology designed to generate high?affinity drug?specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood?brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.